Legal Library: Cases and Proceedings

Forever Living will be permanently prohibited from making deceptive earnings claims to resolve Federal Trade Commission allegations that the company deceived consumers that they could earn profits from the venture when the vast majority of participants made little or no money.

Nevada-based Vanilla Chip LLC, which does business as TruHeight, and its two principals, Eden Stelmach and Justin Rapoport, have agreed to settle the Federal Trade Commission’s charges that they deceptively advertised the effectiveness of a range of supplements touted as supporting height growth in children and teenagers, and relied on reviews that were written by their own employees, or by consumers who were offered a free product or discount in return for writing a 5-star review. 

Publishing.com LLC and its two principals will pay $1.5 million and be required to substantiate earnings claims in the future to settle Federal Trade Commission charges that the company and its operators misled consumers about how much money they were likely to earn using their products.

The FTC alleged that Stormy Wellington used deceptive earnings claims to recruit new members to two multilevel marketing companies.

The FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark Rx, Express Scripts (ESI), and OptumRx—and their affiliated group purchasing organizations (GPOs) for engaging in anticompetitive and unfair rebating practices that have artificially inflated the list price of insulin drugs.

On February 4, 2026, the Federal Trade Commission secured a landmark settlement with Express Scripts, Inc., and its affiliated entities (collectively “ESI”). The settlement requires ESI to adopt fundamental changes to its business practices that increase transparency, are expected to drive down patients’ out-of-pocket costs for drugs like insulin by up to $7 billion over 10 years, bring millions of dollars in new revenue to community pharmacies each year, and advance the Trump Administration’s key healthcare priorities.

In April 2026, the FTC announced that StubHub, the nation’s largest ticket exchange and resale ticket provider, will pay $10 million to settle charges that the company violated the FTC Act and the agency’s Rule on Unfair or Deceptive Fees by deceptively advertising ticket prices on its website without clearly and conspicuously disclosing up-front how much consumers actually would pay, including all mandatory fees.